Apremilast is a kind of PDE-4 inhibitor which was reported to specifically regulate the expression of proinflammatory and anti-inflammatory mediators in psoriasis and it was approved by FDA for the treatment of moderate-to-severe chronic plaque psoriasis.42 To investigate whether alleviation of psoriasis-like phenotype is accompanied by the recovery of intestinal microbiota, K14-VEGF mice (4 M) were treated with apremilast. Here, PDE4A is linked to psoriasis.